拓扑替康周方案在实体肿瘤中应用的研究进展  

Research Progress on the Application of Weekly Topotican in Solid Tumors

作　　者：蒋小雯[1] 张沂平[1] 

机构地区：[1]浙江省肿瘤医院,浙江杭州310022

出　　处：《肿瘤学杂志》2016年第8期673-678,共6页Journal of Chinese Oncology

基　　金：浙江省中医药科研基金项目(2015ZB020);浙江省自然基金(LY13H160024)

摘　　要：拓扑替康(TPT)是一种作用机理独特的抗癌药物,是目前被美国食品药品管理局(FDA)批准用于卵巢癌及小细胞肺癌(SCLC)等实体肿瘤的二线化疗药物。但是TPT标准方案治疗中的不良反应限制了其在临床上的广泛应用,而目前研究表明,TPT周方案治疗实体肿瘤可以在保证具有类似疗效的基础上较标准5d方案能显著降低其不良反应。Topotican（TPT） is an anti-cancer drugs with unique mechanism,which is approved as second-line chemotherapy drugs by the US food and drug administration（FDA） for solid tumors such as ovarian cancer and small cell lung cancer（SCLC）.But the severe toxicity of standard regimen of TPT limits its widely application for clinical.Some recent studies showed that compared with the standard regimen of TPT,the weekly regimen in the treatment of solid tumors could not only ensure the efficacy,but also reduce its toxicity obviously.

关 键 词：肿瘤 拓扑替康 不良反应 

分 类 号：R73[医药卫生—肿瘤]